Amgen Inc. Net Income
Amgen Inc. (AMGN) reported Net Income of $2.38 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-05
- Amgen Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $2.38B, a 65.85% increase year-over-year.
- Amgen Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $1.82B, a 5.14% increase year-over-year.
- Amgen Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $1.33B, a 112.60% increase year-over-year.
- Amgen Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $3.22B, a 13.64% increase year-over-year.
- Amgen Inc. net income (loss) attributable to parent for fiscal 2020 was $7.26B, a 7.37% decline from fiscal 2019.
- Amgen Inc. net income (loss) attributable to parent for fiscal 2019 was $7.84B, a 6.58% decline from fiscal 2018.
- Amgen Inc. net income (loss) attributable to parent for fiscal 2018 was $8.39B, a 324.15% increase from fiscal 2017.
- Amgen Inc. net income (loss) attributable to parent for fiscal 2017 was $1.98B, a 74.37% decline from fiscal 2016.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.38B 10-Q · filed 2026-08-05 | $4.19B 10-Q · filed 2026-08-05 | $5.53B derived: sum of 3 quarters · filed 2026-08-05 | $8.74B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.82B 10-Q · filed 2026-05-01 | $3.15B derived: sum of 2 quarters · filed 2026-05-01 | $6.37B derived: sum of 3 quarters · filed 2026-05-01 | $7.80B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.33B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $4.55B derived: sum of 2 quarters · filed 2026-04-07 | $5.98B derived: sum of 3 quarters · filed 2026-08-05 | $7.71B DEF 14A · filed 2026-04-07 |
| 2025-09-30 | $3.22B 10-Q · filed 2025-11-05 | $4.65B derived: sum of 2 quarters · filed 2026-08-05 | $6.38B 10-Q · filed 2025-11-05 | $7.00B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.43B 10-Q · filed 2026-08-05 | $3.16B 10-Q · filed 2026-08-05 | $3.79B derived: sum of 3 quarters · filed 2026-08-05 | $6.62B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.73B 10-Q · filed 2026-05-01 | $2.36B derived: sum of 2 quarters · filed 2026-05-01 | $5.19B derived: sum of 3 quarters · filed 2026-05-01 | $5.93B derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $627.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $3.46B derived: sum of 2 quarters · filed 2026-04-07 | $4.20B derived: sum of 3 quarters · filed 2026-04-07 | $4.09B DEF 14A · filed 2026-04-07 |
| 2024-09-30 | $2.83B 10-Q · filed 2025-11-05 | $3.58B derived: sum of 2 quarters · filed 2025-11-05 | $3.46B 10-Q · filed 2025-11-05 | $4.23B derived: sum of 4 quarters · filed 2026-04-07 |
| 2024-06-30 | $746.00M 10-Q · filed 2025-08-06 | $633.00M 10-Q · filed 2025-08-06 | $1.40B derived: sum of 3 quarters · filed 2026-04-07 | $3.13B derived: sum of 4 quarters · filed 2026-04-07 |
| 2024-03-31 | -$113.00M 10-Q · filed 2025-05-02 | $654.00M derived: sum of 2 quarters · filed 2026-04-07 | $2.38B derived: sum of 3 quarters · filed 2026-04-07 | $3.76B derived: sum of 4 quarters · filed 2026-04-07 |
| 2023-12-31 | $767.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $2.50B derived: sum of 2 quarters · filed 2026-04-07 | $3.88B derived: sum of 3 quarters · filed 2026-04-07 | $6.72B DEF 14A · filed 2026-04-07 |
| 2023-09-30 | $1.73B 10-Q · filed 2024-10-31 | $3.11B derived: sum of 2 quarters · filed 2024-10-31 | $5.95B 10-Q · filed 2024-10-31 | $7.57B derived: sum of 4 quarters · filed 2026-04-07 |
| 2023-06-30 | $1.38B 10-Q · filed 2024-10-31 | $4.22B 10-Q · filed 2024-08-07 | $5.84B derived: sum of 3 quarters · filed 2026-04-07 | $7.98B derived: sum of 4 quarters · filed 2026-04-07 |
| 2023-03-31 | $2.84B 10-Q · filed 2024-10-31 | $4.46B derived: sum of 2 quarters · filed 2026-04-07 | $6.60B derived: sum of 3 quarters · filed 2026-04-07 | $7.92B derived: sum of 4 quarters · filed 2026-04-07 |
| 2022-12-31 | $1.62B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $3.76B derived: sum of 2 quarters · filed 2026-04-07 | $5.08B derived: sum of 3 quarters · filed 2026-04-07 | $6.55B DEF 14A · filed 2026-04-07 |
| 2022-09-30 | $2.14B 10-Q · filed 2023-10-31 | $3.46B derived: sum of 2 quarters · filed 2023-10-31 | $4.94B 10-Q · filed 2023-10-31 | $6.83B derived: sum of 4 quarters · filed 2026-04-07 |
| 2022-06-30 | $1.32B 10-Q · filed 2023-10-31 | $2.79B 10-Q · filed 2023-08-04 | $4.69B derived: sum of 3 quarters · filed 2026-04-07 | $6.58B derived: sum of 4 quarters · filed 2026-04-07 |
| 2022-03-31 | $1.48B 10-Q · filed 2023-10-31 | $3.38B derived: sum of 2 quarters · filed 2026-04-07 | $5.26B derived: sum of 3 quarters · filed 2026-04-07 | $5.72B derived: sum of 4 quarters · filed 2026-04-07 |
| 2021-12-31 | $1.90B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-07 | $3.78B derived: sum of 2 quarters · filed 2026-04-07 | $4.25B derived: sum of 3 quarters · filed 2026-04-07 | $5.89B DEF 14A · filed 2026-04-07 |
| 2021-09-30 | $1.88B 10-Q · filed 2022-11-04 | $2.35B derived: sum of 2 quarters · filed 2022-11-04 | $3.99B 10-Q · filed 2022-11-04 | $5.61B derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $464.00M 10-Q · filed 2022-11-04 | $2.11B 10-Q · filed 2022-08-05 | $3.73B derived: sum of 3 quarters · filed 2022-11-04 | $5.75B derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-03-31 | $1.65B 10-Q · filed 2022-11-04 | $3.26B derived: sum of 2 quarters · filed 2022-11-04 | $5.28B derived: sum of 3 quarters · filed 2022-11-04 | $7.08B derived: sum of 4 quarters · filed 2022-11-04 |
| 2020-12-31 | $1.61B 10-K · filed 2021-02-09 | $3.64B derived: sum of 2 quarters · filed 2021-11-03 | $5.44B derived: sum of 3 quarters · filed 2021-11-03 | $7.26B 10-K · filed 2023-02-09 |
| 2020-09-30 | $2.02B 10-Q · filed 2021-11-03 | $3.82B derived: sum of 2 quarters · filed 2021-11-03 | $5.65B 10-Q · filed 2021-11-03 | $7.35B derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $1.80B 10-Q · filed 2021-11-03 | $3.63B 10-Q · filed 2021-08-04 | $5.33B derived: sum of 3 quarters · filed 2021-11-03 | $7.30B derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-03-31 | $1.82B 10-Q · filed 2021-11-03 | $3.53B derived: sum of 2 quarters · filed 2021-11-03 | $5.50B derived: sum of 3 quarters · filed 2021-11-03 | $7.67B derived: sum of 4 quarters · filed 2021-11-03 |
| 2019-12-31 | $1.70B 10-K · filed 2021-02-09 | $3.67B derived: sum of 2 quarters · filed 2021-02-09 | $5.85B derived: sum of 3 quarters · filed 2021-02-09 | $7.84B 10-K · filed 2022-02-16 |
| 2019-09-30 | $1.97B 10-K · filed 2021-02-09 | $4.15B derived: sum of 2 quarters · filed 2021-02-09 | $6.14B 10-Q · filed 2020-10-29 | $8.07B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $2.18B 10-K · filed 2021-02-09 | $4.17B 10-Q · filed 2020-07-29 | $6.10B derived: sum of 3 quarters · filed 2021-02-09 | $7.96B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $1.99B 10-K · filed 2021-02-09 | $3.92B derived: sum of 2 quarters · filed 2021-02-09 | $5.78B derived: sum of 3 quarters · filed 2021-02-09 | $8.07B derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $1.93B 10-K · filed 2020-02-12 | $3.79B derived: sum of 2 quarters · filed 2020-02-12 | $6.08B derived: sum of 3 quarters · filed 2020-02-12 | $8.39B 10-K · filed 2021-02-09 |
| 2018-09-30 | $1.86B 10-K · filed 2020-02-12 | $4.16B derived: sum of 2 quarters · filed 2020-02-12 | $6.47B 10-Q · filed 2019-10-30 | $2.20B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $2.30B 10-K · filed 2020-02-12 | $4.61B 10-Q · filed 2019-07-31 | $343.00M derived: sum of 3 quarters · filed 2020-02-12 | $2.36B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $2.31B 10-K · filed 2020-02-12 | -$1.95B derived: sum of 2 quarters · filed 2020-02-12 | $68.00M derived: sum of 3 quarters · filed 2020-02-12 | $2.22B derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | -$4.26B 10-K · filed 2019-02-13 | -$2.24B derived: sum of 2 quarters · filed 2019-02-13 | -$92.00M derived: sum of 3 quarters · filed 2019-02-13 | $1.98B 10-K · filed 2020-02-12 |
| 2017-09-30 | $2.02B 10-K · filed 2019-02-13 | $4.17B derived: sum of 2 quarters · filed 2019-02-13 | $6.24B 10-Q · filed 2018-10-31 | $8.18B derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $2.15B 10-K · filed 2019-02-13 | $4.22B 10-Q · filed 2018-07-27 | $6.16B derived: sum of 3 quarters · filed 2019-02-13 | $8.17B derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $2.07B 10-K · filed 2019-02-13 | $4.01B derived: sum of 2 quarters · filed 2019-02-13 | $6.02B derived: sum of 3 quarters · filed 2019-02-13 | $7.89B derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $1.94B 10-K · filed 2018-02-13 | $3.95B derived: sum of 2 quarters · filed 2018-02-13 | $5.82B derived: sum of 3 quarters · filed 2018-02-13 | $7.72B 10-K · filed 2019-02-13 |
| 2016-09-30 | $2.02B 10-K · filed 2018-02-13 | $3.89B derived: sum of 2 quarters · filed 2018-02-13 | $5.79B 10-Q · filed 2017-10-26 | $7.59B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $1.87B 10-K · filed 2018-02-13 | $3.77B 10-Q · filed 2017-07-26 | $5.57B derived: sum of 3 quarters · filed 2018-02-13 | $7.43B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $1.90B 10-K · filed 2018-02-13 | $3.70B derived: sum of 2 quarters · filed 2018-02-13 | $5.56B derived: sum of 3 quarters · filed 2018-02-13 | $7.22B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $1.80B 10-K · filed 2017-02-14 | $3.66B derived: sum of 2 quarters · filed 2017-02-14 | $5.32B derived: sum of 3 quarters · filed 2017-02-14 | $6.94B 10-K · filed 2018-02-13 |
| 2015-09-30 | $1.86B 10-K · filed 2017-02-14 | $3.52B derived: sum of 2 quarters · filed 2017-02-14 | $5.14B 10-Q · filed 2016-10-28 | $6.43B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $1.65B 10-K · filed 2017-02-14 | $3.28B 10-Q · filed 2016-07-29 | $4.57B derived: sum of 3 quarters · filed 2017-02-14 | $5.81B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $1.62B 10-K · filed 2017-02-14 | $2.92B derived: sum of 2 quarters · filed 2017-02-14 | $4.16B derived: sum of 3 quarters · filed 2017-02-14 | $5.71B derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $1.29B 8-K · filed 2016-10-31 | $2.54B derived: sum of 2 quarters · filed 2016-10-31 | $4.08B derived: sum of 3 quarters · filed 2016-10-31 | $5.16B 10-K · filed 2017-02-14 |
| 2014-09-30 | $1.24B 8-K · filed 2016-10-31 | $2.79B derived: sum of 2 quarters · filed 2016-10-31 | $3.86B 10-Q · filed 2015-11-02 | $4.88B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $1.55B 8-K · filed 2016-10-31 | $2.62B 10-Q · filed 2015-08-05 | $3.64B derived: sum of 3 quarters · filed 2016-10-31 | $5.01B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $1.07B 8-K · filed 2016-10-31 | $2.09B derived: sum of 2 quarters · filed 2016-10-31 | $3.46B derived: sum of 3 quarters · filed 2016-10-31 | $4.72B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $1.02B 10-K · filed 2015-02-19 | $2.39B derived: sum of 2 quarters · filed 2015-02-19 | $3.65B derived: sum of 3 quarters · filed 2015-02-19 | $5.08B 8-K · filed 2016-10-31 |
| 2013-09-30 | $1.37B 10-K · filed 2015-02-19 | $2.63B derived: sum of 2 quarters · filed 2015-02-19 | $4.06B 10-Q · filed 2014-10-29 | $4.85B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $1.26B 10-K · filed 2015-02-19 | $2.69B 10-Q · filed 2014-08-05 | $3.48B derived: sum of 3 quarters · filed 2015-02-19 | $4.59B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $1.43B 10-K · filed 2015-02-19 | $2.22B derived: sum of 2 quarters · filed 2015-02-19 | $3.33B derived: sum of 3 quarters · filed 2015-02-19 | $4.59B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $788.00M 10-K · filed 2014-02-24 | $1.90B derived: sum of 2 quarters · filed 2014-02-24 | $3.16B derived: sum of 3 quarters · filed 2014-02-24 | $4.34B 10-K · filed 2015-02-19 |
| 2012-09-30 | $1.11B 10-K · filed 2014-02-24 | $2.37B derived: sum of 2 quarters · filed 2014-02-24 | $3.56B 10-Q · filed 2013-10-29 | $4.49B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $1.27B 10-K · filed 2014-02-24 | $2.45B 10-Q · filed 2013-08-06 | $3.38B derived: sum of 3 quarters · filed 2014-02-24 | $3.84B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $1.18B 10-K · filed 2014-02-24 | $2.12B derived: sum of 2 quarters · filed 2014-02-24 | $2.57B derived: sum of 3 quarters · filed 2014-02-24 | $3.74B derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $934.00M 10-K · filed 2013-02-27 | $1.39B derived: sum of 2 quarters · filed 2013-02-27 | $2.56B derived: sum of 3 quarters · filed 2013-02-27 | $3.68B 10-K · filed 2014-02-24 |
| 2011-09-30 | $454.00M 10-K · filed 2013-02-27 | $1.62B derived: sum of 2 quarters · filed 2013-02-27 | $2.75B 10-Q · filed 2012-11-06 | $3.77B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $1.17B 10-K · filed 2013-02-27 | $2.29B 10-Q · filed 2012-08-08 | $3.32B derived: sum of 3 quarters · filed 2013-02-27 | $4.55B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $1.13B 10-K · filed 2013-02-27 | $2.15B derived: sum of 2 quarters · filed 2013-02-27 | $3.38B derived: sum of 3 quarters · filed 2013-02-27 | $4.58B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $1.02B 10-K · filed 2012-02-29 | $2.26B derived: sum of 2 quarters · filed 2012-02-29 | $3.46B derived: sum of 3 quarters · filed 2012-02-29 | $4.63B 10-K · filed 2013-02-27 |
| 2010-09-30 | $1.24B 10-K · filed 2012-02-29 | $2.44B derived: sum of 2 quarters · filed 2012-02-29 | $3.60B 10-Q · filed 2011-11-04 | $4.54B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $1.20B 10-K · filed 2012-02-29 | $2.37B 10-Q · filed 2011-08-08 | $3.30B derived: sum of 3 quarters · filed 2012-02-29 | $4.69B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $1.17B 10-K · filed 2012-02-29 | $2.10B derived: sum of 2 quarters · filed 2012-02-29 | $3.48B derived: sum of 3 quarters · filed 2012-02-29 | $4.75B derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $931.00M 10-K · filed 2011-02-25 | $2.32B derived: sum of 2 quarters · filed 2011-02-25 | $3.59B derived: sum of 3 quarters · filed 2011-02-25 | $4.61B 10-K · filed 2012-02-29 |
| 2009-09-30 | $1.39B 10-K · filed 2011-02-25 | $2.65B derived: sum of 2 quarters · filed 2011-02-25 | $3.67B 10-Q · filed 2010-11-08 | $4.60B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $1.27B 10-K · filed 2011-02-25 | $2.29B 10-Q · filed 2010-08-09 | $3.21B derived: sum of 3 quarters · filed 2011-02-25 | $4.33B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $1.02B 10-K · filed 2011-02-25 | $1.94B derived: sum of 2 quarters · filed 2011-02-25 | $3.06B derived: sum of 3 quarters · filed 2011-02-25 | $3.97B derived: sum of 4 quarters · filed 2011-02-25 |
| 2008-12-31 | $925.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $2.05B derived: sum of 2 quarters · filed 2011-02-25 | $2.95B derived: sum of 3 quarters · filed 2011-02-25 | $4.05B 10-K · filed 2011-02-25 |
| 2008-09-30 | $1.12B 10-Q · filed 2009-11-06 | $2.03B derived: sum of 2 quarters · filed 2009-11-06 | $3.13B 10-Q · filed 2009-11-06 | |
| 2008-06-30 | $906.00M 10-Q · filed 2009-08-10 | $2.01B 10-Q · filed 2009-08-10 | ||
| 2007-12-31 | $3.08B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |